含有SPRY结构域的SOCS盒蛋白SPSB1,SPSB2和SPSB4利用其SPRY/B30.2结构域与诱导型一氧化氮合酶(iNOS)的N末端的短区相互作用,并招募E3泛素连接酶复合物以聚泛素化iNOS,导致iNOS的蛋白酶体降解。可以破坏内源性SPSB-iNOS相互作用的抑制剂可用于增加细胞NO的产生,并可能具有抗菌和抗癌活性。我们以前报道了环肽抑制剂的合理设计,cR8,循环(RGDINNNV),以中等亲和力与SPSB2结合。我们,因此,寻求开发具有更高亲和力的SPSB抑制剂。这里,我们显示环状肽cR7,环状(RGDINNN),和cR9,循环(RGDINNVE),具有〜6.5倍和〜2倍,分别,SPSB2-bindng亲和力高于cR8。我们确定了SPSB2-cR7和SPSB2-cR9复合物的高分辨率晶体结构,这使得能够很好地理解这些环肽抑制剂的结构-活性关系。此外,我们显示这些环肽取代了SPSB2,SPSB1和SPSB4的全长iNOS,并且它们的抑制效力与其SPSB2结合亲和力密切相关。观察到cR7对所有三种iNOS结合SPSB蛋白的最强抑制作用。
The SPRY domain-containing SOCS box proteins SPSB1, SPSB2, and SPSB4 utilize their SPRY/B30.2 domain to interact with a short region in the N-terminus of inducible nitric oxide synthase (iNOS), and recruit an E3 ubiquitin ligase complex to polyubiquitinate iNOS, resulting in the proteasomal degradation of iNOS. Inhibitors that can disrupt the endogenous SPSB-iNOS interactions could be used to augment cellular NO production, and may have antimicrobial and anticancer activities. We previously reported the rational design of a cyclic peptide
inhibitor, cR8, cyclo(RGDINNNV), which bound to SPSB2 with moderate affinity. We, therefore, sought to develop SPSB inhibitors with higher affinity. Here, we show that cyclic peptides cR7, cyclo(RGDINNN), and cR9, cyclo(RGDINNNVE), have ~6.5-fold and ~2-fold, respectively, higher SPSB2-bindng affinities than cR8. We determined high-resolution crystal structures of the SPSB2-cR7 and SPSB2-cR9 complexes, which enabled a good understanding of the structure-activity relationships for these cyclic peptide inhibitors. Moreover, we show that these cyclic peptides displace full-length iNOS from SPSB2, SPSB1, and SPSB4, and that their inhibitory potencies correlate well with their SPSB2-binding affinities. The strongest inhibition was observed for cR7 against all three iNOS-binding SPSB proteins.